Scriven A J, Lipkin D P, Anand I S, Sutton G C, Poole-Wilson P A
Cardiothoracic Institute, London, U.K.
J Cardiovasc Pharmacol. 1988 Jan;11(1):45-50. doi: 10.1097/00005344-198801000-00007.
Enoximone (MDL 17043, 150 mg t.d.s.) and captopril (25 mg t.d.s.) were compared as additional treatment to diuretics in 13 patients with severe chronic heart failure in a cross-over, double-blind, and randomised trial. Each treatment was continued for one month. Heart failure was due to cardiomyopathy in six patients and ischaemic heart disease in seven. Exercise capacity and central haemodynamics at rest and on exercise were measured on entry to the study and after each treatment period. Cardiac index at peak exercise time and peak oxygen consumption were increased by both drugs, but there were no differences in these increases between the two drugs after one month's treatment. Minor differences were found in the biochemical and hormonal response to the two drugs. Those patients who improved on captopril also improved on enoximone.
在一项交叉、双盲、随机试验中，对13例重度慢性心力衰竭患者，比较了依诺昔酮（MDL 17043，每日三次，每次150毫克）和卡托普利（每日三次，每次25毫克）作为利尿剂辅助治疗的效果。每种治疗持续一个月。6例患者的心力衰竭由心肌病引起，7例由缺血性心脏病引起。在研究开始时以及每个治疗期后，测量静息和运动时的运动能力及中心血流动力学。两种药物均使运动高峰时的心指数和峰值耗氧量增加，但治疗一个月后，两种药物在这些增加量方面无差异。发现两种药物在生化和激素反应方面存在细微差异。那些对卡托普利有反应的患者对依诺昔酮也有反应。
